Intriguingly, it has been suggested that secondary CAPS may be involved in the development of thrombosis in COVID-19 patients [137], and indeed lupus anticoagulant (LA), antiphospholipid (auto) antibodies (aPL-Abs) and β2 glycoprotein 1 (β2-GP1) autoantibodies have been identified in COVID-19 patients [138,139,140,141]. This evidence concerns the gene APOH and COVID-19.